Pipeline news
-
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
12 May 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2022.
-
09 May 2022
Ernst & Young LLP (EY US) announced that Jeff Luber, Chief Executive Officer of binx health, has been named an Entrepreneur Of The Year® 2022 New England Award finalist. Entrepreneur Of The Year is one of the preeminent competitive business awards for entrepreneurs and leaders of high-growth companies who think big to succeed.
-
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
05 May 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has resumed screening and recruitment for the Phase 3 RAISE (Randomized Therapy in Status Epilepticus) trial in refractory status epilepticus (RSE). The company continues to expect topline RAISE trial results in the second half of 2023.
-
04 May 2022
binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, has partnered with student health insurer Wellfleet to broaden access to human papillomavirus (HPV) testing through convenient, at-home sample collection. The companies believe this joint initiative will encourage more Americans to get tested for HPV, in the settings and at the times most convenient for them. The Biden Administration highlighted HPV infections among its key areas of focus in its Cancer Moonshot reignition announcement earlier this year.
-
14 April 2022
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that The Lancet Neurology has publishedresults from the pivotal Phase 3 Marigold trial of ZTALMY® (ganaxolone) for the treatment of seizures associated with CDKL5 deficiency disorder (CDD). The paper, “Efficacy and safety of ganaxolone in patients with CDKL5 deficiency disorder: a randomized, double-blind, placebo-controlled, Phase 3 trial,” can be accessed on The Lancet Neurology website.
-
05 April 2022
Epic Sciences, Inc. has added DefineMBC™, a novel comprehensive blood-based test for characterizing metastatic breast cancer, to its CLIA laboratory menu.
-
binx health Appoints Life Sciences Veteran Jack Crowley as Chief Financial Officer
05 April 2022
binx health, a healthcare technology and diagnostics company, announced today the appointment of Jack Crowley as Chief Financial Officer (CFO). Crowley brings deep industry expertise in life sciences and demonstrated results in successful initial and secondary public offerings, capital structure enhancements, analyst collaboration, and investor relations.
-
01 April 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has received $30 million in funding under the existing Oaktree Capital Management, L.P. (Oaktree) credit agreement. This additional funding became available as a result of the U.S. Food and Drug Administration’s (FDA) recent approval of the company’s New Drug Application (NDA) for ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older.
-
binx health Voted as Finalist in Medical Design Excellence Awards 2022
30 March 2022
binx health, a healthcare technology and diagnostics company is pleased to announce its selection as a finalist in the Medical Design Excellence Awards 2022. The Medical Design Excellence Awards (MDEA) is the premier awards program for the medtech industry with a mission to recognize significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.
-
21 March 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.
